Months into his second term, President Donald Trump’s top health officials were clear. They promised to focus on “cures” and “meaningful treatments.” They wanted revolutionary medicine to be developed in the United States . They didn’t want the treatments of tomorrow to come from China. But a concerning new ideological shift at the Food and Drug Administration threatens to undermine these worthy goals — from within. Patients are frustrated, and are waiting longer for groundbreaking treatments.

Tag-uri: Donald Trump